CN114306635A - 包含可裂解接头的化合物及其用途 - Google Patents

包含可裂解接头的化合物及其用途 Download PDF

Info

Publication number
CN114306635A
CN114306635A CN202111628316.1A CN202111628316A CN114306635A CN 114306635 A CN114306635 A CN 114306635A CN 202111628316 A CN202111628316 A CN 202111628316A CN 114306635 A CN114306635 A CN 114306635A
Authority
CN
China
Prior art keywords
group
independently
formula
antibody
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111628316.1A
Other languages
English (en)
Chinese (zh)
Inventor
朴泰教
禹成昊
金璇暎
朴秀浩
赵钟云
丁头焕
徐东勋
李在镐
李相光
尹尚铉
河智贤
李享俶
朴沃龟
徐范硕
金世娜
薛旻娥
宋真我
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yintusaili Co ltd
Original Assignee
Yintusaili Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yintusaili Co ltd filed Critical Yintusaili Co ltd
Publication of CN114306635A publication Critical patent/CN114306635A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202111628316.1A 2019-01-03 2020-01-02 包含可裂解接头的化合物及其用途 Pending CN114306635A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962788039P 2019-01-03 2019-01-03
US62/788,039 2019-01-03
CN202080007805.2A CN113423431A (zh) 2019-01-03 2020-01-02 包含可裂解接头的化合物及其用途
PCT/IB2020/000019 WO2020141460A2 (en) 2019-01-03 2020-01-02 Compounds comprising cleavable linker and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080007805.2A Division CN113423431A (zh) 2019-01-03 2020-01-02 包含可裂解接头的化合物及其用途

Publications (1)

Publication Number Publication Date
CN114306635A true CN114306635A (zh) 2022-04-12

Family

ID=71407384

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202111628316.1A Pending CN114306635A (zh) 2019-01-03 2020-01-02 包含可裂解接头的化合物及其用途
CN202080007805.2A Pending CN113423431A (zh) 2019-01-03 2020-01-02 包含可裂解接头的化合物及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080007805.2A Pending CN113423431A (zh) 2019-01-03 2020-01-02 包含可裂解接头的化合物及其用途

Country Status (7)

Country Link
US (1) US12551570B2 (https=)
EP (1) EP3906063A4 (https=)
JP (2) JP7657153B2 (https=)
KR (1) KR20210099658A (https=)
CN (2) CN114306635A (https=)
EA (1) EA202191855A1 (https=)
WO (1) WO2020141460A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120682290A (zh) 2017-07-04 2025-09-23 尹图赛利有限公司 包含可裂解接头的化合物及其用途
KR20210099658A (ko) 2019-01-03 2021-08-12 주식회사 인투셀 절단가능 링커를 포함하는 화합물 및 이의 용도
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法
CN114874287B (zh) * 2022-05-20 2024-04-02 联宁（苏州）生物制药有限公司 一种抗体偶联药物-连接子lnd1042的合成方法
WO2025252011A1 (zh) * 2024-06-03 2025-12-11 杭州多域生物技术有限公司 含Sulfoximine连接子的降解剂及其中间体和应用
CN119462688B (zh) * 2024-11-08 2026-03-10 青岛大学 一种生物素化氨基酸衍生物的制备方法
CN121494812A (zh) * 2026-01-14 2026-02-10 西南林业大学 一种基于肉桂酸衍生物的n2h4比率型荧光探针及其合成方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5279920A (en) * 1991-11-01 1994-01-18 Konica Corporation Silver halide photographic light sensitive material
JP2005291974A (ja) * 2004-03-31 2005-10-20 Kyocera Chemical Corp フェルダジル基を有する磁性有機粒子、粒子固定方法及びマイクロアレイ
CN105358579A (zh) * 2014-05-28 2016-02-24 乐高化学生物科学股份有限公司 包含自脱落基团的化合物
US20180110874A1 (en) * 2014-01-10 2018-04-26 Birdie Biopharmaceuticals, Inc. Compounds and Compositions for Immunotherapy
WO2018124758A2 (ko) * 2016-12-28 2018-07-05 주식회사 인투셀 베타-갈락토사이드가 도입된 자가-희생 기를 포함하는 화합물

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1182232B (de) 1963-03-08 1964-11-26 Hans J Zimmer Verfahrenstechni Verfahren zur Herstellung von Trialkylaryloxysilanen
CH565791A5 (https=) 1972-07-11 1975-08-29 Sandoz Ag
US4540828A (en) 1982-06-01 1985-09-10 Vista Chemical Company Catalysts for alkoxylation reactions
JPS5978171A (ja) 1982-10-26 1984-05-04 Ikeda Mohandou:Kk 複素環式化合物
DE3632329A1 (de) 1986-09-24 1988-03-31 Bayer Ag Substituierte phenylsulfonamide
ATE218132T1 (de) 1994-10-14 2002-06-15 Yamanouchi Pharma Co Ltd Azol-derivate
EP1867729A1 (en) 2006-06-14 2007-12-19 Libragen Water soluble phenolics derivatives with dermocosmetic and therapeutic applications
CN104185477B (zh) 2011-11-17 2017-05-24 辉瑞公司 细胞毒性肽及其抗体‑药物缀合物
TWI585115B (zh) 2011-12-15 2017-06-01 普利司通股份有限公司 經穩定之多價陰離子聚合反應引發劑及其製備方法
ES2781523T3 (es) 2012-07-12 2020-09-02 Hangzhou Dac Biotech Co Ltd Conjugados de moléculas de unión celular con agentes citotóxicos
US9834575B2 (en) 2013-02-26 2017-12-05 Triact Therapeutics, Inc. Cancer therapy
US9499528B2 (en) 2013-04-08 2016-11-22 The University Of Akron Class of near infrared molecular probes for biological applications
WO2016029324A1 (en) 2014-08-29 2016-03-03 Rsem, Limited Partnership Azasulfurylpeptide-based cd36 modulators and uses thereof
US10035526B2 (en) 2014-12-03 2018-07-31 New York Air Brake, LLC Brake piston assembly
US10370407B2 (en) 2015-01-21 2019-08-06 The Regents Of The University Of California Affinity-assisted protein modification and recycling
CN107922375B (zh) 2015-07-30 2020-05-22 正大天晴药业集团股份有限公司 靶向idh2突变的抗肿瘤化合物及其使用方法
WO2017044043A1 (en) 2015-09-09 2017-03-16 Agency For Science, Technology And Research Process for direct amidation of amines via rh(i)-catalyzed addition of boroxines
KR101766822B1 (ko) 2015-09-10 2017-08-24 서울대학교산학협력단 디페닐설페이트 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 c형 간염 바이러스 관련 질환의 예방 또는 치료용 약학적 조성물
AU2016359235B2 (en) 2015-11-25 2022-09-15 Ligachem Biosciences Inc. Antibody-drug conjugates comprising branched linkers and methods related thereto
WO2018053552A2 (en) 2016-09-19 2018-03-22 Cellerant Therapeutics, Inc. Isoquinolidinobenzodiazepines
CN120682290A (zh) * 2017-07-04 2025-09-23 尹图赛利有限公司 包含可裂解接头的化合物及其用途
MX2020012718A (es) 2018-05-29 2021-02-16 Intocell Inc Derivados de benzodiazepinas novedosos y usos de los mismos.
CN112930350A (zh) 2018-10-31 2021-06-08 尹图赛利有限公司 稠合杂环苯并二氮杂䓬衍生物及其用途
WO2020141459A1 (en) 2019-01-03 2020-07-09 Intocell, Inc. Compounds comprising cleavable linker and uses thereof
KR20210099658A (ko) 2019-01-03 2021-08-12 주식회사 인투셀 절단가능 링커를 포함하는 화합물 및 이의 용도

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5279920A (en) * 1991-11-01 1994-01-18 Konica Corporation Silver halide photographic light sensitive material
JP2005291974A (ja) * 2004-03-31 2005-10-20 Kyocera Chemical Corp フェルダジル基を有する磁性有機粒子、粒子固定方法及びマイクロアレイ
US20180110874A1 (en) * 2014-01-10 2018-04-26 Birdie Biopharmaceuticals, Inc. Compounds and Compositions for Immunotherapy
CN105358579A (zh) * 2014-05-28 2016-02-24 乐高化学生物科学股份有限公司 包含自脱落基团的化合物
US20160184451A1 (en) * 2014-05-28 2016-06-30 Legochem Biosciences, Inc. Compounds comprising self-immolative group
WO2018124758A2 (ko) * 2016-12-28 2018-07-05 주식회사 인투셀 베타-갈락토사이드가 도입된 자가-희생 기를 포함하는 화합물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ADEL M. ELSOHLY等: "Synthetically Modified Viral Capsids as Versatile Carriers for Use in Antibody-Based Cell Targeting", 《BIOCONJUGATE CHEMISTRY ARTICLE》, vol. 26, 15 June 2015 (2015-06-15), pages 1590 - 1596, XP055728784, DOI: 10.1021/acs.bioconjchem.5b00226 *
ALEXANDRA GOUASMAT等: "Catalytic Iron(III) Chloride Mediated Site-Selective Protection of Mono- and Disaccharides and One Trisaccharide", 《EUR. J. ORG. CHEM.》, 31 December 2017 (2017-12-31), pages 3355 - 3361 *

Also Published As

Publication number Publication date
JP2022515885A (ja) 2022-02-22
JP7657153B2 (ja) 2025-04-04
EA202191855A1 (ru) 2021-11-19
EP3906063A2 (en) 2021-11-10
US20210393795A1 (en) 2021-12-23
WO2020141460A3 (en) 2020-08-27
JP2025020144A (ja) 2025-02-12
EP3906063A4 (en) 2023-03-01
CN113423431A (zh) 2021-09-21
WO2020141460A2 (en) 2020-07-09
KR20210099658A (ko) 2021-08-12
US12551570B2 (en) 2026-02-17

Similar Documents

Publication Publication Date Title
AU2023216777B2 (en) Compounds comprising cleavable linker and uses thereof
CN114306635A (zh) 包含可裂解接头的化合物及其用途
TWI765864B (zh) 關於抗-cd19抗體藥物共軛物之組合物及方法
JP7657152B2 (ja) 切断可能なリンカーを含む化合物及びその使用
TW201722480A (zh) 關於抗-egfr抗體藥物共軛物之組合物及方法
RU2795168C2 (ru) Соединения, содержащие расщепляемый линкер, и способы их применения
HK40030386A (en) Compounds comprising cleavable linker and uses thereof
CN120393042A (zh) 含季铵盐的抗体偶联药物及其医药用途
HK1216180B (zh) 包含自脱落基团的化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination